Drug-Associated Risk of Subacute Cutaneous Lupus Erythematosus: A Pharmacovigilance Study of the FDA Adverse Event Reporting System

Abstract

Keywords

subacute cutaneous lupus erythematosus adverse event real world FAERS pharmacovigilance

Get full access to this article

View all access options for this article.

References

Chong

. Understanding how cutaneous lupus erythematosus progresses to systemic lupus erythematosus. JAMA Dermatol. 2014;150(3):296. doi:10.1001/jamadermatol.2013.9030

Reed

Huff

Jones

Orton

Lee

Norris

. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103(1):49-51. doi:10.7326/0003-4819-103-1-49

Lowe

Henderson

Grau

Hansen

Sontheimer

. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465-472. doi:10.1111/j.1365-2133.2010.10110.x

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.62 MB